Moldavsko -
rumunčina -
AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)
biemexol 350 350 mg/ml soluţie injectabilă
biem ilac sanayii ve ticaret a.s. - iohexolum - soluţie injectabilă - 350 mg/ml
Moldavsko -
rumunčina -
AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)
tomohexol 350 mg i/ml soluţie injectabilă
farmak sap - iohexolum - soluţie injectabilă - 350 mg i/ml
Moldavsko -
rumunčina -
AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)
tomohexol 350 mg i/ml soluţie injectabilă
farmak sap - iohexolum - soluţie injectabilă - 350 mg i/ml
Moldavsko -
rumunčina -
AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)
tomohexol 350 mg i/ml soluţie injectabilă
farmak sa - iohexolum - soluţie injectabilă - 350 mg i/ml
Európska únia -
rumunčina -
EMA (European Medicines Agency)
tysabri
biogen netherlands b.v. - natalizumab - scleroză multiplă - imunosupresoare selective - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 și 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
Európska únia -
rumunčina -
EMA (European Medicines Agency)
tyruko
sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresoare - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 și 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.
Rumunsko -
rumunčina -
ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)
voriconazol sandoz 50 mg
lek pharmaceuticals d.d. - slovenia - voriconazolum - compr. film. - 50mg - antimicotice de uz sistemic derivati de triazol
Rumunsko -
rumunčina -
ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)
voriconazol sandoz 200 mg
lek pharmaceuticals d.d. - slovenia - voriconazolum - compr. film. - 200mg - antimicotice de uz sistemic derivati de triazol
Moldavsko -
rumunčina -
AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)
pilfud 50 mg/ml spray cutanat, soluţie
bosnalijek, pharmaceutical and chemical industry jsc - minoxidil - spray cutanat, soluţie - 50 mg/ml